SCEMBLIX 40 mg Oral Tablet
RxNorm 2584330
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2584330 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: SCEMBLIX 40 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
Asciminib 40 mg Oral Tablet [Scemblix]
(Atom ID: 12710233)
SYPrescribable
Synonym (SY):
Scemblix 40 mg (equivalent to asciminib HCl 43.24 mg) Oral Tablet
(Atom ID: 12898200)
PSNPrescribable
Prescribable Name (PSN):
SCEMBLIX 40 mg Oral Tablet
(Atom ID: 12710235)
SYPrescribable
Synonym (SY):
Scemblix 40 mg Oral Tablet
(Atom ID: 12710234)
Patient Education
Asciminib
Asciminib is used to treat a certain type of chronic myeloid leukemia (CML; a type of cancer of the white blood cells) as a first treatment and in people who can no longer benefit from other leukemia medications. Asciminib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
[Learn More]
* Please review the disclaimer below.